Analysts forecast that DBV TECHNOLOGIE/S (NASDAQ:DBVT) will post earnings per share of ($0.52) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for DBV TECHNOLOGIE/S’s earnings. The firm is expected to report its next earnings report on Monday, January 1st.
According to Zacks, analysts expect that DBV TECHNOLOGIE/S will report full year earnings of ($2.43) per share for the current financial year, with EPS estimates ranging from ($2.72) to ($2.11). For the next financial year, analysts forecast that the business will post earnings of ($1.97) per share, with EPS estimates ranging from ($2.25) to ($1.65). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for DBV TECHNOLOGIE/S.
DBVT has been the subject of a number of research reports. ValuEngine raised shares of DBV TECHNOLOGIE/S from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Goldman Sachs Group assumed coverage on shares of DBV TECHNOLOGIE/S in a research report on Monday, June 17th. They issued a “buy” rating and a $14.00 price target on the stock. BidaskClub upgraded shares of DBV TECHNOLOGIE/S from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Zacks Investment Research lowered shares of DBV TECHNOLOGIE/S from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and five have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $14.81.
DBV TECHNOLOGIE/S stock traded up $0.21 during mid-day trading on Tuesday, hitting $8.98. The company’s stock had a trading volume of 59,900 shares, compared to its average volume of 173,700. The company has a quick ratio of 3.30, a current ratio of 3.34 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $528.97 million, a P/E ratio of -2.65 and a beta of 1.82. DBV TECHNOLOGIE/S has a twelve month low of $3.60 and a twelve month high of $25.77. The stock’s fifty day moving average price is $9.63 and its two-hundred day moving average price is $8.78.
DBV TECHNOLOGIE/S Company Profile
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in children, adolescents, and adults.
See Also: Buyback For Investors Defined
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for DBV TECHNOLOGIE/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV TECHNOLOGIE/S and related companies with MarketBeat.com's FREE daily email newsletter.